Axogen, Inc.
0HKD.L
London Stock Exchange43.12
USD
-3.09
- -
Axogen, Inc.
0HKD.L
(London Stock Exchange)
Recent
price
43.12
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- AxoGen, Inc. (NASDAQ: AXGN; LSE: 0HKD) develops, manufactures, and commercializes technologies for peripheral nerve regeneration and repair. The company offers a comprehensive portfolio of surgical solutions including Avance Nerve Graft, an acellular processed human nerve allograft for bridging nerve gaps; Axoguard Nerve Connector, a porcine submucosa extracellular matrix (ECM) tube for entubulation protection and reinforcement of nerve repairs; Axoguard Nerve Protector, a porcine submucosa ECM product to wrap and protect damaged peripheral nerves; Axoguard Nerve Cap, a device to protect nerve ends from neuroma formation; Axoguard HA+ Nerve Protector, a next-generation porcine ECM with hyaluronate-alginate gel coating for short- and long-term nerve protection; and Avive Soft Tissue Matrix and Avive+ Soft Tissue Matrix, multi-layer amniotic membrane allografts to modulate the surgical bed and separate tissues during repair. These products serve reconstructive plastic surgeons, orthopedic and plastic hand surgeons, oral and maxillofacial surgeons, neurosurgeons, and other specialists performing nerve repair procedures in hospitals, surgery centers, and military facilities. AxoGen targets the $2.7 billion peripheral nerve repair market across approximately 900,000 annual procedures in the United States, with primary applications in trauma, orthopedic, reconstructive, neurosurgery, and oral/maxillofacial segments. Founded in 2002 and headquartered in Alachua, Florida, the company operates primarily in the United States with additional facilities in Tampa, Florida; Burleson, Texas; and Dayton, Ohio. In a major recent development, AxoGen received U.S. FDA approval for its Biologics License Application (BLA) for AVANCE Nerve Graft (acellular nerve allograft–arwx) on December 3, 2025, enhancing its regulatory standing and market potential. The company also reported strong financial performance, including Q3 2025 revenue growth across all markets, raised full-year 2025 revenue guidance to at least 19% or $222.8 million, expanded payer coverage to over 64% commercial penetration adding 18.1 million lives, and anticipates net cash flow positivity for 2025.